Snapshot from Jun 08, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Scantox Launches DuplexSeq App
Tech product launch

Scantox Launches DuplexSeq App

Analysis based on 6 articles · First reported May 12, 2026 · Last updated May 12, 2026

Sentiment
60
Attention
2
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch of the DuplexSeq Mutagenesis App by Scantox, hosted on LatchBio's platform, is expected to positively impact the biotechnology and pharmaceutical industries by providing a faster, more accessible, and scalable error-corrected sequencing methodology. This development could enhance genomic safety assessments and streamline nonclinical mutagenesis studies for companies in these sectors.

Biotechnology Pharmaceuticals Information technology
Event Summary

Scantox Group announced the launch of the Scantox DuplexSeq Mutagenesis App, hosted on an upgraded bioinformatics platform provided by LatchBio. This launch restores customer access to DuplexSeq Mutagenesis Assays with expanded supply expected in Q3 2026 and a scalable bioinformatics pipeline. Clint Valentine of Fulcrum Genomics led the migration, ensuring scientific rigor and continuity. The platform is designed to meet regulated nonclinical science standards, offering features like one-click execution, centralized data management, and improved data visualization. This advancement positions DuplexSeq as a leading error-corrected sequencing methodology for genomic safety.

Key Actions
100 Scantox launched app
80 Scantox selected LatchBio
70 Clint Valentine led migration LatchBio
Entities Involved
priv
Scantox
Scantox launched the DuplexSeq Mutagenesis App, hosted on an upgraded bioinformatics platform, enhancing its error-corrected sequencing technology and expanding its service offerings.
Importance 100 Sentiment 70
priv
LatchBio
LatchBio was selected by Scantox to host the DuplexSeq Mutagenesis App, providing its bioinformatics platform with enterprise-grade security and compliance for regulated nonclinical science.
Importance 80 Sentiment 60
priv
Fulcrum Genomics
Fulcrum Genomics' Vice President of Operations, Clint Valentine, led the migration of the DuplexSeq pipeline to LatchBio, ensuring continuity and scientific rigor.
Importance 50 Sentiment 40
per
Clint Valentine
Clint Valentine, Vice President of Operations at Fulcrum Genomics, was instrumental in migrating the DuplexSeq pipeline to LatchBio, ensuring its scientific integrity.
Importance 50 Sentiment 40
per
Matt Tate
Matt Tate, Chief Business Development Officer at Scantox, highlighted the enhanced speed and accessibility of the DuplexSeq platform.
Importance 40 Sentiment 30
per
Kyle Giffin
Kyle Giffin, Chief Operating Officer of LatchBio, emphasized LatchBio's compliance with data integrity and audit readiness standards for DuplexSeq customers.
Importance 40 Sentiment 30
oth
Impilo
Impilo is the owner of Scantox, which launched the DuplexSeq Mutagenesis App.
Importance 20 Sentiment 30
priv
TwinStrand Biosciences
TwinStrand Biosciences' original validation dataset was used to confirm equivalent outputs and pipeline continuity during the migration of DuplexSeq.
Importance 0 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.